497 related articles for article (PubMed ID: 18691016)
21. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain.
Inoue M; Ma L; Aoki J; Chun J; Ueda H
Mol Pain; 2008 Feb; 4():6. PubMed ID: 18261210
[TBL] [Abstract][Full Text] [Related]
22. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression.
Panupinthu N; Lee HY; Mills GB
Br J Cancer; 2010 Mar; 102(6):941-6. PubMed ID: 20234370
[TBL] [Abstract][Full Text] [Related]
23. Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions.
Nakasaki T; Tanaka T; Okudaira S; Hirosawa M; Umemoto E; Otani K; Jin S; Bai Z; Hayasaka H; Fukui Y; Aozasa K; Fujita N; Tsuruo T; Ozono K; Aoki J; Miyasaka M
Am J Pathol; 2008 Nov; 173(5):1566-76. PubMed ID: 18818380
[TBL] [Abstract][Full Text] [Related]
24. Measurement of autotaxin/lysophospholipase D activity.
Morris AJ; Smyth SS
Methods Enzymol; 2007; 434():89-104. PubMed ID: 17954243
[TBL] [Abstract][Full Text] [Related]
25. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
[TBL] [Abstract][Full Text] [Related]
26. Production of extracellular lysophosphatidic acid in the regulation of adipocyte functions and liver fibrosis.
Yang F; Chen GX
World J Gastroenterol; 2018 Sep; 24(36):4132-4151. PubMed ID: 30271079
[TBL] [Abstract][Full Text] [Related]
27. Targeting the autotaxin - Lysophosphatidic acid receptor axis in cardiovascular diseases.
Zhao Y; Hasse S; Zhao C; Bourgoin SG
Biochem Pharmacol; 2019 Jun; 164():74-81. PubMed ID: 30928673
[TBL] [Abstract][Full Text] [Related]
28. Autotaxin/Lysophosphatidic Acid Axis: From Bone Biology to Bone Disorders.
Alioli C; Demesmay L; Peyruchaud O; Machuca-Gayet I
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408784
[TBL] [Abstract][Full Text] [Related]
29. Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.
Zhang R; Wang J; Ma S; Huang Z; Zhang G
BMC Cell Biol; 2011 Mar; 12():11. PubMed ID: 21406114
[TBL] [Abstract][Full Text] [Related]
30. Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration.
Ptaszynska MM; Pendrak ML; Stracke ML; Roberts DD
Mol Cancer Res; 2010 Mar; 8(3):309-21. PubMed ID: 20197381
[TBL] [Abstract][Full Text] [Related]
31. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid.
Inoue M; Xie W; Matsushita Y; Chun J; Aoki J; Ueda H
Neuroscience; 2008 Mar; 152(2):296-8. PubMed ID: 18280050
[TBL] [Abstract][Full Text] [Related]
32. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.
Gotoh M; Fujiwara Y; Yue J; Liu J; Lee S; Fells J; Uchiyama A; Murakami-Murofushi K; Kennel S; Wall J; Patil R; Gupte R; Balazs L; Miller DD; Tigyi GJ
Biochem Soc Trans; 2012 Feb; 40(1):31-6. PubMed ID: 22260662
[TBL] [Abstract][Full Text] [Related]
33. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.
Albers HM; Dong A; van Meeteren LA; Egan DA; Sunkara M; van Tilburg EW; Schuurman K; van Tellingen O; Morris AJ; Smyth SS; Moolenaar WH; Ovaa H
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7257-62. PubMed ID: 20360563
[TBL] [Abstract][Full Text] [Related]
34. Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors.
Tabchy A; Tigyi G; Mills GB
Nat Struct Mol Biol; 2011 Feb; 18(2):117-8. PubMed ID: 21289650
[TBL] [Abstract][Full Text] [Related]
35. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.
Orosa B; García S; Conde C
Eur J Pharmacol; 2015 Oct; 765():228-33. PubMed ID: 26297977
[TBL] [Abstract][Full Text] [Related]
36. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
[TBL] [Abstract][Full Text] [Related]
37. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate.
Song J; Clair T; Noh JH; Eun JW; Ryu SY; Lee SN; Ahn YM; Kim SY; Lee SH; Park WS; Yoo NJ; Lee JY; Nam SW
Biochem Biophys Res Commun; 2005 Nov; 337(3):967-75. PubMed ID: 16219296
[TBL] [Abstract][Full Text] [Related]
38. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT
Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138
[TBL] [Abstract][Full Text] [Related]
39. Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases.
Gendaszewska-Darmach E
Acta Biochim Pol; 2008; 55(2):227-40. PubMed ID: 18560605
[TBL] [Abstract][Full Text] [Related]
40. Autotaxin regulates vascular development via multiple lysophosphatidic acid (LPA) receptors in zebrafish.
Yukiura H; Hama K; Nakanaga K; Tanaka M; Asaoka Y; Okudaira S; Arima N; Inoue A; Hashimoto T; Arai H; Kawahara A; Nishina H; Aoki J
J Biol Chem; 2011 Dec; 286(51):43972-43983. PubMed ID: 21971049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
